Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

543
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
543
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

479
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
479
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

844
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
844
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

1.4K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.4K
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

941
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
941
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

202
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
202

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative analysis of phytochemical traits, proximate composition, and metabolite diversity in Nigella sativa L. genotypes from India.

Scientific reports·2026
Same author

Spatial Modeling of Anthrax Risk in India's Agro-Climatic Zones: A Future Perspective.

Acta tropica·2026
Same author

Isolation and complete genome analysis of Porcine Parvovirus 1 from swine with reproductive failure in southern India.

Archives of microbiology·2026
Same author

Isolation and complete genome analysis of porcine circovirus-1 associated with reproductive failurein swine: foremost study in India.

Archives of microbiology·2025
Same author

Exploring the diagnostic utility of recombinant low molecular weight cystic fluid proteins, Ag2 and Ag2V1, for serosurveillance of porcine cysticercosis.

Experimental parasitology·2025
Same author

Development of an enzyme immunoassay employing low molecular weight recombinant Ag1 and Ag1V1 proteins of cystic fluid for the serodiagnosis of porcine cysticercosis.

Veterinary parasitology·2025
Same journal

The Effect of Vitamin D on the Humoral Immune Response of Calves to the Sheeppox Virus Vaccine.

Archives of Razi Institute·2026
Same journal

Expression Analysis of BCL-2 in Endometrial Hyperplasia and Carcinoma: The Powers and Limitations.

Archives of Razi Institute·2026
Same journal

Evaluation of Inflammatory Markers (PV, ESR, CRP) in the Early Diagnosis of Cancer and Their Relationship With Survival Rate.

Archives of Razi Institute·2026
Same journal

Antibacterial Photodynamic Therapy Using Zinc Phthalocyanine Against Multidrug-resistant <i>Pseudomonas aeruginosa</i> in Burn Infections.

Archives of Razi Institute·2026
Same journal

Hematologic and Computed Tomography Features for Discriminating COVID-19 From Non-COVID-19 Pneumonia.

Archives of Razi Institute·2026
Same journal

A Case of Urothelial Carcinoma in Situ of the Bladder in Local Dog in Bali, Indonesia.

Archives of Razi Institute·2026
See all related articles

Related Experiment Video

Updated: Jan 17, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K

Advanced Therapeutic Interventions Targeting Mycobacterium Tuberculosis.

A A Razzak Mahmood1, V I Rani2, P Yadav3

  • 1Department of Pharmaceutical Chemistry, College of Pharmacy, University of Baghdad. Bab Al-Mouadam, 10001. Baghdad, Iraq.

Archives of Razi Institute
|September 15, 2025
PubMed
Summary
This summary is machine-generated.

Tuberculosis infection (TBI) remains a global threat, particularly affecting vulnerable populations. Advances in diagnostics, prophylactic therapies, and AI integration offer promising strategies for improved TBI treatment and patient care.

Keywords:
High-Risk GroupsSocio-Economic FactorsTuberculosisInfection (TBI)Vulnerable PopulationsMycobacterium Tuberculosis (M.tb)

More Related Videos

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Related Experiment Videos

Last Updated: Jan 17, 2026

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis
09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

2.2K
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
09:57

System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

Published on: April 5, 2017

9.0K
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

8.3K

Area of Science:

  • Infectious Diseases
  • Public Health
  • Medical Research

Background:

  • Tuberculosis infection (TBI), caused by Mycobacterium tuberculosis, is a persistent global health threat.
  • HIV/AIDS, vulnerable populations, and socioeconomic factors exacerbate TBI prevalence.
  • The COVID-19 pandemic has disrupted TBI diagnosis and treatment, impacting patient outcomes.

Purpose of the Study:

  • To review vulnerable populations, high-risk groups, and socioeconomic factors influencing TBI prevalence.
  • To explore the intersection of TBI and the COVID-19 pandemic.
  • To discuss advances in TBI diagnosis, treatment, and the integration of artificial intelligence (AI).

Main Methods:

  • Literature review examining TBI prevalence, risk factors, and global impact.
  • Analysis of diagnostic advancements, including biomarkers like interferon-gamma release assays (IGRAs).
  • Evaluation of prophylactic therapies (e.g., isoniazid preventive therapy) and combination treatments for drug-resistant strains.
  • Exploration of AI's role in optimizing TBI treatment and personalizing patient care.

Main Results:

  • Vulnerability to TBI is influenced by age, socioeconomic status, and immune status.
  • High-risk groups include immunocompromised individuals, the elderly, and those in crowded settings.
  • Improved biomarkers and prophylactic therapies show potential in reducing active TB risk.
  • AI integration offers personalized treatment plans for better TBI management.
  • The COVID-19 pandemic has negatively impacted TBI diagnosis and care, with telemedicine emerging as a potential long-term solution.

Conclusions:

  • TBI remains a significant global health challenge requiring innovative diagnostic and therapeutic strategies.
  • Advances in diagnostics, prophylactic therapies, combination treatments, and AI integration hold promise for improved TBI outcomes.
  • Addressing socioeconomic factors and healthcare access is crucial for TBI control.